Analysis and Revive Therapeutics Ltd (RVV) Earnings Review

Share with your friends


Analysts await Revive Therapeutics Ltd (CVE:RVV) to reports earnings on September, 29. The stock closed at $0.5 during the last session. It is down 6.00% since August 28, 2015 and is uptrending. It has outperformed by 14.45% the S&P500.

Analysis and Revive Therapeutics Ltd (RVV) Earnings Review

Revive Therapeutics Ltd., formerly Mercury Capital II Limited, is focused on acquiring, developing and commercializing treatments for major market opportunities such as sleep apnea, gout and rare diseases. The company has a market cap of $11.97 million. The Firm is focused on underserved medical needs such as opioid-induced respiratory depression in high risk patients with sleep apnea, gout, and Rett Syndrome. It currently has negative earnings.

Revive Therapeutics Ltd - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.